DepoMed (NAS: DEPO) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), DepoMed crushed expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly and GAAP earnings per share contracted to a loss.
Margins dropped across the board.
DepoMed tallied revenue of $16.8 million. The five analysts polled by S&P Capital IQ predicted revenue of $12.7 million on the same basis. GAAP reported sales were 80% lower than the prior-year quarter's $83.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.16. The five earnings estimates compiled by S&P Capital IQ forecast -$0.24 per share. GAAP EPS were -$0.16 for Q1 versus $1.77 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 96.9%, 110 basis points worse than the prior-year quarter. Operating margin was -53.1%, 12,390 basis points worse than the prior-year quarter. Net margin was -52.3%, 17,120 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $14.5 million. On the bottom line, the average EPS estimate is -$0.23.
Next year's average estimate for revenue is $66.2 million. The average EPS estimate is -$0.79.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 236 members out of 252 rating the stock outperform, and 16 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 45 give DepoMed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DepoMed is buy, with an average price target of $9.10.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is DepoMed the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
Add DepoMed to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.